Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 16:15:53.
doi: 10.1186/s12872-015-0043-z.

Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study

Toru Kubo  1 , Yuichi Baba  2 , Takayoshi Hirota  3 , Katsutoshi Tanioka  4 , Naohito Yamasaki  5 , Shigeo Yamanaka  6 , Tatsuo Iiyama  7 , Naoko Kumagai  8 , Takashi Furuno  9 , Tetsuro Sugiura  10 , Hiroaki Kitaoka  11
Affiliations

Differentiation of infiltrative cardiomyopathy from hypertrophic cardiomyopathy using high-sensitivity cardiac troponin T: a case-control study

Toru Kubo et al. BMC Cardiovasc Disord. .

Abstract

Background: Because infiltrative cardiomyopathy and hypertrophic cardiomyopathy (HCM) share clinical and hemodynamic features of left ventricular (LV) hypertrophy and abnormal diastolic function, it is often difficult to distinguish these entities.

Methods: We investigated the potential role of high-sensitivity cardiac troponin T (hs-cTnT) for differentiation of infiltrative cardiomyopathy from HCM.

Results: The study group consisted of 46 consecutive patients with infiltrative cardiomyopathies or HCM in whom sarcomere protein gene mutations were identified at Kochi Medical School Hospital; of these, there were 11 patients with infiltrative cardiomyopathy (cardiac amyloidosis in 8 patients and Fabry disease in 3 patients) and 35 HCM patients. Serum hs-cTnT level was significantly higher in patients who had infiltrative cardiomyopathy than in those who had HCM (0.083 ± 0.057 ng/ml versus 0.027 ± 0.034 ng/ml, p < 0.001), whereas brain natriuretic peptide levels did not differ between the two groups. In two age-matched the 2 cohorts (patients evaluated at > 40 years at age), hs-cTnT level, maximum LV wall thickness, posterior wall thickness, peak early (E) transmitral filling velocity, peak early diastolic (Ea) velocity of tissue Doppler imaging at the lateral corner and E/Ea ratios at both the septal and lateral corners were significantly different between the two groups. As for diagnostic accuracy to differentiate the two groups by using receiver operating characteristic analysis, hs-cTnT was the highest value of area under the curve (0.939) and E/Ea (lateral) was second highest value (0.914).

Conclusions: Serum hs-cTnT is a helpful diagnostic indicator for accurate differentiation between infiltrative cardiomyopathy and HCM.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Long-axis two-dimensional echocardiograms (diastole phase) of patients with cardiomyopathies. a: a cardiac amyloidosis patient with concentric left ventricular (LV) hypertrophy, b: a cardiac amyloidosis patient with asymmetric septal hypertrophy (ASH) at first glance (but actually concentric hypertrophy rather than ASH if moderator band is removed), c: a cardiac Fabry patient with concentric LV hypertrophy, d: a cardiac Fabry patient with ASH (in a terminal stage patient with Fabry disease, LV systolic dysfunction with localized thinning of the base of the LV posterior wall is seen.), e: a hypertrophic cardiomyopathy (HCM) patient with ASH, f: a HCM patient with concentric LV hypertrophy at first glance
Fig. 2
Fig. 2
The distribution of hs-cTnT and BNP values. Hs-cTnT: high-sensitivity cardiac troponin T, BNP: brain natriuretic peptide
Fig. 3
Fig. 3
The distribution of hs-cTnT and E/Ea (lateral) values. Hs-cTnT: high-sensitivity cardiac troponin T, E: peak early transmitral filling velocity, Ea (lateral): peak early diastolic velocity of mitral annulus velocities at lateral corner
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidosis. N Engl J Med. 1997;337:898–909. doi: 10.1056/NEJM199709253371306. - DOI - PubMed
    1. Cueto-Garcia L, Reeder GS, Kyle RA, Wood DL, Seward JB, Naessens J, Offorrd KP, Greipp PR, Edwards WD, Tajik AJ. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737–43. doi: 10.1016/S0735-1097(85)80475-7. - DOI - PubMed
    1. Falk RH, Plehn JF, Deering T, Schick EC, Jr, Boinay P, Rubinow A, Skinner M, Cohen AS. Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol. 1987;59:418–22. doi: 10.1016/0002-9149(87)90948-9. - DOI - PubMed
    1. Palka P, Lange A, Donnelly JE, Scalia G, Burstow DJ, Nihoyannopoulos P. Doppler tissue echocardiographic features of cardiac amyloidosis. J Am Soc Echocardiogr. 2002;15:1353–60. doi: 10.1067/mje.2002.125285. - DOI - PubMed
    1. Oki T, Tanaka H, Yamada H, Tabata T, Oishi Y, Ishimoto T, Nagase N, Shinohara H, Salabe K, Fukuda N. Diagnosis of cardiac amyloidosis based on the myocardial velocity profile in the hypertrophied left ventricular wall. Am J Cardiol. 2004;93:864–9. doi: 10.1016/j.amjcard.2003.12.025. - DOI - PubMed

MeSH terms

Supplementary concepts